Back to Journals Drug Design, Development and Therapy Volume 13 The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date Authors Antza C , Nirantharakumar K , Doundoulakis I, Tahrani AA, Toulis KA Received 31 October 2018 Accepted for publication 27 June 2019 Published 22 August 2019 Volume 2019:13 Pages 29852996 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Tuo Deng Christina Antza, 1,* Krishnarajah Nirantharakumar, 2,* Ioannis Doundoulakis, 3 Abd A Tahrani, 46 Konstantinos A Toulis 2, 3 1 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece
GHK-Cu: Overview GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptidemetal complex identified in biological fluids and extracellular matrices
For peptides with short activity windows, schedule becomes part of the dose itself
Good for general digestive upset
We are accepting new patient appointments for GLP-1 weight loss management
Rodent healing differs from human healing in various ways, and dose extrapolation involves assumptions that may not hold perfectly
